Angiopoietin-like protein 4 (ANGPTL4), a newly developed diagnostic and prognostic biomarker, acts as a potential therapy target for renal cell carcinoma, prostate cancer and hepatocellular carcinoma [27,28,29]. This evidence concerns the gene ANGPTL4 and prostate carcinoma.